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ABSTRACT:	  Mupirocin,	   a	   clinically	   important	   antibiotic	   produced	   via	   a	   trans-­‐AT	  Type	   I	   polyketide	   synthase	   (PKS)	   in	  
Pseudomonas	  fluorescens,	  consists	  of	  a	  mixture	  of	  mainly	  pseudomonic	  acids	  A,	  B	  and	  C.	  Detailed	  metabolic	  profiling	  of	  
mutant	  strains	  produced	  by	  systematic	  inactivation	  of	  PKS	  and	  tailoring	  genes,	  along	  with	  re-­‐feeding	  of	  isolated	  metabo-­‐
lites	   to	   mutant	   stains,	   has	   allowed	   the	   isolation	   of	   a	   large	   number	   of	   novel	   metabolites,	   identification	   of	   the	   10,11-­‐
epoxidase	  and	  the	  full	  characterisation	  of	  the	  mupirocin	  biosynthetic	  pathway	  which	  proceeds	  via	  major	  (10,11-­‐epoxide)	  
and	  minor	  (10,11-­‐alkene)	  parallel	  pathways.	  	  
INTRODUCTION	  
Mupirocin,	  a	  mixture	  of	  pseudomonic	  acids,	  produced	  by	  
Pseudomonas	   fluorescens	   NCIMB	   10586,	   is	   a	   clinically	  
important	   antibiotic	   against	   Gram	   positive	   bacteria,	   in-­‐
cluding	   methicillin-­‐resistant	   Staphylococcus	   aureus	  
(MRSA).1,2	  It	  inhibits	  bacterial	  isoleucyl-­‐transfer	  RNA	  syn-­‐
thetase	   and	   is	   currently	   the	   standard	   treatment	   used	  
worldwide	   for	   the	   topical	   control	   of	   MRSA.3	   The	   major	  
component	  of	  mupirocin	  is	  pseudomonic	  acid	  A	  (1,	  PA-­‐A,	  
Fig.	  1),	  which	  accounts	  for	  ca	  90%	  of	  the	  mixture.4	  It	  was	  
identified	  as	  one	  of	  the	  first	  of	  an	  extensive	  family	  of	  anti-­‐
biotics	   produced	   by	   the	   “trans-­‐AT”	   class	   of	   modular	  
polyketide	   synthases	   (PKS).5	   	   It	   consists	   of	   a	   C17	   polyke-­‐
tide-­‐derived	   substructure	   (monic	   acid)	   esterified	   by	   9-­‐
hydroxynonanoic	   acid	   (9-­‐HN).	   The	   other	   main	   compo-­‐
nents	  are	  pseudomonic	  acid	  B	  (2,	  PA-­‐B,	  8%)	  which	  has	  an	  
additional	  hydroxyl	  group	  at	  C8,6	   and	  pseudomonic	  acid	  
C	  (3,	  PA-­‐C,	  <	  2%)	  which	  has	  a	  double	  bond	  in	  place	  of	  the	  
epoxide	  group	  at	  C10-­‐C11.7	  PA-­‐D	  	  (1,	  4’-­‐5’-­‐alkene)	  has	  also	  
been	  reported	  as	  a	  very	  minor	  component.	  Simple	  biosyn-­‐
thetic	   logic	  would	  suggest	  that	  PA-­‐A	  is	   formed	  by	  epoxi-­‐
dation	  of	  the	  10,11-­‐double	  bond	  in	  PA-­‐C	  3,	  and	  PA-­‐B	  2,	  by	  
a	  further	  hydroxylation	  of	  PA-­‐A	  at	  C8.	  	  
Novel	  pseudomonic	  acid	  analogues,	  the	  thiomarinols,	  e.g.	  
thiomarinol	  A	  4,	  and	  also	  active	  against	  MRSA	  have	  been	  
isolated	   from	   marine	   organisms,	   e.g.,	   Alteromonas	   sp.	  
SANK	   73390.8	   The	   thiomarinols	   are	   closely	   related	   to	  
mupirocin,9	  being	  produced	  by	  a	  very	  similar	  biosynthetic	  
gene	   cluster10	  with	   the	   addition	  of	   a	  non-­‐ribosomal	  pep-­‐
tide	   synthase	   (NRPS)-­‐encoded	   pyrrothine	   moiety	   at-­‐
tached	  via	  an	  amide	  to	  an	  8-­‐hydroxyoctanoic	  acid	  moiety.	  
The	   74-­‐kb	  mupirocin	   biosynthetic	   gene	   cluster	   (Fig.	   2A)	  
encodes	   six	   modular	   multifunctional	   proteins	   (Mmps)	  
involved	  in	  polyketide	  and	  fatty	  acid	  biosynthesis	  and	  26	  
single	  enzymes	  originally	   thought	   to	  perform	   largely	   tai-­‐
loring	  functions.11	  The	  first	  half	  of	  the	  cluster	  contains	  two	  
large	   Type	   I	   multifunctional	   PKS	   genes	   (mmpA	   and	  D)	  
plus	   associated	   trans-­‐acyltransferases	   (mmpC),	   an	   itera-­‐
tive	  Type	  I	  FAS	  (mmpB),	  as	  well	  as	  two	  single	  ORFs	  mupA	  
and	  mupB,	   while	   the	   second	   half	   contains	   twenty	   seven	  
single	  ORFs	   (mupC-­‐X,	  macpA-­‐E),	   plus	   two	   smaller	   PKS-­‐
like	  genes	  	  mmpE	  and	  	  mmpF.	  MmpD	  and	  MmpA	  togeth-­‐
er	  contain	  six	  modules	  for	  condensation	  and	  reduction	  of	  
acetate-­‐derived	  units,	  which	  with	  two	  methyl	  transferase	  	  
	  
	  











































Figure	   2.	  A,	   a	   summary	   of	   the	  mupirocin	   biosynthetic	   gene	   cluster.	   The	  HCS	   cassette	   responsible	   for	  β-­‐branching	   is	  
shown	  in	  grey.	  B,	  formalized	  scheme	  for	  the	  biosynthesis	  of	  monic	  acid	  and	  its	  elaboration	  to	  muprocin.	  “Grey”	  domains	  
are	  inactive	  or	  non-­‐functional	  in	  chain	  elongation.	  Tailoring	  proteins	  acting	  in	  trans	  are	  indicated	  as	  elongated	  domains.	  
domains	   could	   generate	   the	   backbone	   of	   a	   C17-­‐
heptaketide	   monic	   acid	   precursor	   (I).	   Module	   6	   of	  
MmpA,	  the	  final	  module	  involved	  in	  monic	  acid	  biosyn-­‐
thesis,	  contains	  twin	  ACPs	  each	  with	  a	  unique	  recogni-­‐
tion	   motif	   specific12	   for	   association	   with	   the	   “β-­‐
hydroxymethylglutaryl-­‐CoA	   synthase”	   (HCS)	   cassette	  
(MupG,	  H,	   J	   and	  K	  and	  MacpC)	   responsible	   for	   the	   in-­‐
troduction	  of	  the	  15-­‐methyl	  β-­‐branch	  (!	  in	  II)13.	  9-­‐HN	  is	  
likely	   formed	   from	   a	   3-­‐hydroxy-­‐propionate	   starter	   unit	  
extended	   by	   three	   malonate	   condensations	   by	   MmpB	  
functioning	   as	   an	   iterative	   FAS	   with	   additional	   enoyl	  
reductase	   (ER)	   activity,	   perhaps	   provided	   by	   MupE	  
and/or	   MupD.14	   The	   resulting	   backbone	   would	   need	  
further	  modifications	   to	   produce	   the	  major	  metabolite	  
PA-­‐A.	  
In-­‐frame	  deletions	  demonstrated	  that	  all	  of	  the	  proteins	  
are	  required	  for	  mupirocin	  production.14	  However,	  many	  
uncertainties	  remain,	  particularly	   in	  the	  timing	  of	   10,11-­‐
epoxidation,	   tetrahydropyran	   (THP)	   ring	   formation,	   6-­‐
hydroxylation,	   fatty	   acid	   chain	   extension,	   and	   the	   pre-­‐
cise	  roles	  of,	   inter	  alia:	   the	  mupW	  (dioxygenase),	  mupC	  
(oxidoreductase),	   mupF	   (ketoreductase),	   mupU	   (acyl	  
CoA	   synthase),	   mupO	   (P450),	   mupV	   oxidoreductase),	  
macpE	   (acyl	   carrier	   protein),	   and	   mmpE	   (ketosyn-­‐
thase/oxidoreductase)	  gene	  products.	  	  
Previous	  work	  on	  mutant	  strains	  containing	  single	  dele-­‐
tions	  of	  these	  genes	  led	  to	  the	  isolation	  of	  several	  novel	  
PAs,	   including	  mupirocin	  W1	  5,15	  mupirocin	  C2	   1614	   and	  
mupirocin	   F1	   18a16	   (previously	   named	   mupricins	  W,	   C	  
and	  F)	  from	  ∆mupW,	  ∆mupC	  and	  ∆mupF	  strains	  respec-­‐
tively	   (Figs.	   3	   and	   4	   below).	   The	   tetrahydrofuran-­‐
containing	   metabolites	   5	   and	   16	   are	   likely	   rearrange-­‐
ment	  products	   formed	  by	   attack	   of	   a	   7-­‐hydroxyl	   group	  
onto	   C-­‐10	   of	   the	   labile	   epoxide.	   Deletions	   of	   mupV,	  
mupO,	  mupU	  and	  macpE	  all	  resulted	  in	  a	  switch	  to	  pro-­‐
duction	  of	  PA-­‐B	  2	   only17	   and	   the	  corresponding	  double	  
mutants	   with	   addition	   of	   a	  ∆mupC	   mutation	   gave	   the	  
same	   result	   suggesting	   that	  mupV,	  mupO,	  mupU	   and	  
macpE	   all	   act	   before	  mupC,	   and	   by	   implication	  mupF.	  
This	   led	   to	   the	   conclusion	   that	   PA-­‐B	   2	   is	   produced	   ei-­‐
ther	   as	   a	   result	   of	   a	   branch	   in	   the	   pathway17	   or	   that	   it	  
could	  be	  a	  precursor	  leading	  to	  PA-­‐A	  1	  as	  had	  been	  pro-­‐
posed	  but	  not	  proven	  by	  Mantle	  et	  al.18	  The	  10,11-­‐epoxide	  
in	  PA-­‐A	  1	  makes	   it	   susceptible	   to	   intramolecular	  attack	  
by	  the	  7-­‐OH	  outside	  a	  narrow	  pH	  range,	  which	  limits	  its	  
clinical	  utility.2	  PA-­‐C	  3,	   lacking	   the	  epoxide	   is	   similarly	  
active	  to	  PA-­‐A	  1	  but	  it	  is	  much	  more	  stable.	  Thus	  a	  de-­‐
sirable	  goal	  in	  terms	  of	  obtaining	  a	  clinically	  more	  useful	  
antibiotic	  would	  be	  to	  knock	  out	  the	  epoxidase	  activity	  
and	  channel	  production	  entirely	  to	  PA-­‐C	  3.	  Further	  cor-­‐
relation	   of	   tailoring	   genes	   with	   catalytic	   function	   and	  
resulting	   chemical	  modification	  was	  made	  difficult	  due	  
to	   the	  so-­‐called	  “leaky-­‐hosepipe”	  mechanism19	   in	  which	  
mutations	  of	  the	  HCS	  cassette	  and	  many	  others	  all	  pro-­‐
duce	   an	   essentially	   identical	   phenotype	   in	  which	  pseu-­‐
domonic	  acid	  biosynthesis	  is	  blocked	  and	  two	  truncated	  
metabolites	  mupiric	  acid	  13	  and	  mupirocin	  H	  14	   (Fig	  3)	  
are	  isolated.	  (Mupirocin	  H	  is	  proposed19	  to	  result	  from	  a	  
retro-­‐aldol	  cleavage	  of	  intermediate	  25	  in	  Scheme	  1	  –	  see	  
below).	   This	   phenotype	   was	   attributed	   to	   spontaneous	  
release	   of	   these	   two	   compounds	   at	   chemically	   labile	  
points,	  as	  a	  result	  of	   impeding	  metabolic	  flux	  along	  the	  
assembly	   pathway	   by	   any	   mutation	   which	   interferes	  
with	  formation	  of	  monic	  acid	  or	  its	  subsequent	  esterifi-­‐
cation	  by	  the	  MmpB-­‐derived	  FAS.	  
We	   now	   report	   detailed	   investigations	   on	   mupirocin	  
bosynthesis	  involving	  single	  and	  double	  gene	  knockouts	  
leading	   to	   new	   insights	   into	   this	   complex	   pathway,	   in-­‐
cluding	   association	   of	   MmpE	   with	   introduction	   of	   the	  
10.11-­‐epoxide.	   Single	   mutants	   as	   well	   as	   the	  WT	   strain	  
were	   grown	   on	   a	   modified	   L-­‐medium	   which	   crucially	  
allowed	  more	   facile	   isolation	   of	  minor	  metabolites	   not	  
previously	  observed	  in	  these	  strains.	  Similarly,	  a	  series	  of	  
double	   mutants	   were	   analysed	   under	   the	   same	   condi-­‐
tions,	   and	   intermediates	   isolated	   in	   these	   experiments	  
were	  re-­‐fed	  to	  mutant	  strains.	  As	  a	  result	  of	  these	  stud-­‐
ies	  definitive	  evidence	  has	  been	  obtained	  for	  the	  biosyn-­‐
thetic	  relationships	  among	  previously	  reported	  and	  nov-­‐
el	  pseudomonic	  acid	  metabolites,	  showing	  the	  presence	  
of	  two	  parallel	  pathways,	  one	  major	  and	  one	  minor	  (see	  
Scheme	  1),	  and	  that	  epoxidation,	  tetrahydropyran	  ring	  	  
 	  
Figure	  3.	  (A)	  Known	  and	  novel	  (*)	  metabolites	  isolated	  from	  extracts	  of	  WT	  and	  selected	  mutant	  strains	  of	  P.	  fluorescens.	  
WT	  also	  contains	  PA-­‐A	  and	  PA-­‐B	  as	  the	  major	  products	  and	  a	  trace	  amount	  of	  PA-­‐C.	  Metabolites	  in	  LH	  column	  are	  epox-­‐
ide	  derived,	  RH	  column	  are	  10,11-­‐alkenes.	  Some	  compounds	  have	  been	  renamed	  to	  take	  account	  of	  new	  metabolites	  iso-­‐
lated.	   (B)	   HPLC	   traces	   of	   extracts	   of	   (a)	   WT,	   (b)	   mmpEΔOR,	   (c)	   ΔmupW,	   (d)	   mmpEΔOR/ΔmupW	   strains.
formation,	   and	   6-­‐hydroxylation	   are	   necessary	   for	   effi-­‐
cient	  downstream	  metabolic	  processing.	  
RESULTS	  AND	  DISSCUSSION	  
Analysis	  of	  WT	  and	  mutant	  strains	  
We	  first	   investigated	  metabolite	  production	  by	   the	  WT	  
strain	   of	  P.	   fluorescens	  NCIMB	   10586	   cultivated	   on	   the	  
modified	  L-­‐medium	   to	  determine	   if	   any	  previously	  un-­‐
detected	  minor	  metabolites	  were	  present	   (see	  Support-­‐
ing	  	  Information	  for	  details).	  PA-­‐A	  1	  (ca.	  50	  mg.L-­‐1),	  PA-­‐B	  
2,	  and	  PA-­‐C	  3	  were	  isolated	  (Fig.	  3B(a)	  and	  Table	  1).	  Fur-­‐
ther	  detailed	   analysis	   of	  minor	   components	   resulted	   in	  
the	  isolation	  of	  mupirocin	  W	  515	  and	  its	  analogue	  mupi-­‐
rocin	   W2	   6	   containing	   a	   shorter	   (C7)	   fatty	   acid	   side	  
chain,	   as	   well	   as	   four	   new	   mupirocin	   metabolites	   of	  
which	   one,	   a	  macrolactonic	   derivative	   12	   of	   PA-­‐B	   con-­‐
tained	   the	   10,11-­‐epoxide.	   The	   other	   three	   metabolites	  
are:	  mupirocin	  W4	  9	  and	  mupirocin	  W5	  10	   each	  with	  a	  
10,11-­‐alkene	  and	  hence	   lacking	   the	   tetrahydrofuran	   ring	  
formed	   via	   the	   labile	   10,11-­‐epoxide,	   and	   10,11-­‐desepoxy-­‐
PA-­‐B	   11	   (Fig.	   3B(b)).	   These	   were	   isolated	   and	   purified,	  
and	   their	   structures	   determined	   by	   full	   NMR	   analysis	  
and	   HR-­‐ESI-­‐MS	   (see	   SI	   for	   details).	   These	   metabolites	  
form	   two	   structurally	   distinct	   groups.	   The	   first	   group	  
contains	  the	  10,11-­‐epoxide	  (1,	  2	  and	  12)	  or	  rearrangement	  
products	   (5	   and	   6)	   derived	   from	   it;	   while	   the	   second	  
group	   lack	   the	  epoxide	  and	  contain	  a	   10,11-­‐alkene	   (3,	  9,	  
10,	  and	  11).	  This	  suggests	  that	  the	  first	  group	  of	  PAs	  (1,	  2,	  
5,	  6	   and	   12)	  which	  account	   for	  97%	  of	   total	  PAs	   in	   the	  
WT	   strain	   (Table	   1)	   are	   intermediates,	   shunt	   or	   final	  
natural	   products	   generated	   from	   the	   same	   dominant	  
biosynthetic	  pathway,	  while	  a	  minor	  pathway	   involving	  
intermediates	  lacking	  the	  10,11-­‐epoxide	  is	  responsible	  for	  
the	  second	  group	  of	  PAs	  accounting	   for	   1%	  of	   the	   total	  
yield	  of	  PAs.	  	  
Previous	  studies14	  failed	  to	  identify	  a	  monofunctional	  
gene	   encoding	   a	   10,11-­‐epoxidase.	   We	   therefore	   consid-­‐
ered	   domains	   of	   multifunctional	   proteins.	   One	   such	  
candidate	   is	   the	   bifunctional	  MmpE	  which	  has	   a	   puta-­‐
tive	  N-­‐terminal	   KS	   and	   a	   putative	  C-­‐terminal	   oxidore-­‐
ductase	   (MmpEOR).	   Deletion	   (aa789	   to	   aa1173)	   of	   the	  
predicted	   MmpEOR	   domain	   and	   HPLC	   analysis	   (Fig.	  
3B(b))	   indicated	   that	   production	   of	   PAs	   with	   a	   10,11-­‐
epoxide	   or	   derived	   functionality	   are	   completely	   abol-­‐
ished	  and	  only	  PAs	  with	  a	  10,11-­‐alkene	  (PA-­‐C	  3,	  mupiro-­‐
cins	  W4	  and	  W5	  9	  and	  10,	  and	  desepoxy	  PA-­‐B	  11)	  accu-­‐
mulate	   in	   the	   mmpE∆OR	   mutant,	   consistent	   with	  
mmpEOR	   encoding	   the	   10,11-­‐epoxidase.	   The	   titres	   of	  
these	   10,11-­‐alkenes	   (2.6	   -­‐	   1.1	   mg.L-­‐1)	   isolated	   from	   the	  
mmpE∆OR	  mutant,	  while	  somewhat	  higher	  than	  in	  WT	  
(0.4	  -­‐	  0.2	  mg.L-­‐1,	  Table	  1),	  remain	  very	  low.	  
As	  indicated	  above	  mutation	  of	  mupW,15	  and	  also	  mupT	  
(which	   encode	   a	   putative	   dioxygenase	   and	   associated	  
ferredoxin	   dioxygenase	   respectively),	   produce	   mupiro-­‐
cin	  W1	  5	  lacking	  the	  THP	  ring	  and	  so	  these	  genes	  appear	  
to	   be	   responsible	   for	   the	   oxidative	   activation	   required	  
for	  the	  formation	  of	  the	  ring.15	  In	  this	  study,	  we	  first	  re-­‐
fermented	  ∆mupW:	  HPLC	  (Fig.	  3B(c))	  showed	  the	  pres-­‐
ence	  of	  5,	   and	   its	  7-­‐hydroxyheptanoate	  analogue	  mupi-­‐
rocin	  W2	  6	   (each	  ca	   1	  mg.L-­‐1).	  The	  ∆mupT	  mutant	  gave	  
identical	   results	   (data	   not	   shown).	   Interestingly	   a	   dou-­‐
ble	   ∆mupW/∆mupO	   mutant	   (originally	   constructed	   to	  
test	   the	  relative	   timing	  of	  action	  of	  MupW	  and	  MupO)	  
gave	   slightly	   higher	   titres	   of	   5	   and	   6	   and	   also	   allowed	  
detection	   of	   smaller	   amounts	   of	   mupirocin	   W3	   7,	   an	  
analogue	   containing	   a	   further	   truncated	   5-­‐hydroxy-­‐
pentanoate	   side	   chain	   and	   significantly,	  mupirocin	  W6	  
8,	  the	  only	  monic	  acid	  analogue	  so	  far	  isolated	  lacking	  a	  
fatty	   acid	   side	   chain.	   	   To	   explore	   the	   relationship	   be-­‐
tween	  epoxidation	  and	  other	  tailoring	  steps,	  the	  double	  
mutant	   mmpE∆OR/∆mupW	   was	   then	   examined.	   Pro-­‐
duction	  of	  5	  and	  6	  was	  abolished,	  and	  only	  their	  desoxy	  	  
 	  
	  
Table	  1.	  Pseudomonic	  acids	  isolated	  from	  WT	  and	  mutant	  strains.	  	  
aNew	  PAs	  reported	  for	  the	  first	  time	  in	  this	  study;	  bPAs	  derived	  from	  minor	  pathway.	  Values	  are	  given	  in	  mg.L-­‐1.	  
	  
Figure	  4.	  (A)	  Known	  and	  novel	  (*)	  metabolites	  isolated	  from	  extracts	  of	  selected	  mutant	  strains	  of	  P.	  fluorescens.	  LH	  col-­‐
umn	  are	  epoxide	  derived,	  RH	  column	  are	  10,11-­‐alkenes.	  Some	  compounds	  have	  been	  renamed	  to	  take	  account	  of	  new	  me-­‐
tabolites	  isolated.	  (B)	  HPLC	  traces	  of	  extracts	  of	  (a)	  ΔmupC,	  (b)	  mmpEΔOR/ΔmupC,	  (c)	  ΔmupF,	  (d)	  mmpEΔOR/ΔmupF	  
10,11-­‐alkene	   analogues,	   mupirocins	   W4	   9	   and	   W5	   10	  
(each	   ca	   1.5	   mg.L-­‐1)	   accumulated	   (Fig.	   3B(d).	   Although	  
the	   actual	   substrates	   for	   MupW/T	   and	   MmpEOR	   re-­‐
mained	  to	  be	  established	  (see	  below),	   it	   is	  notable	   that	  
MmpE	   (Fig.	   2)	   is	   positioned	   immediately	   after	   the	  “
HCS	   cassette”	   responsible	   for	   the	   introduction	   of	   the	  
β-­‐branch	   15-­‐methyl.13	   Also	   in	   the	   related	   thiomarinol	  
gene	   cluster10	   the	   tmlK	   and	   tmpE	  genes	   are	   fused	   (Fig.	  
S2),	   encoding	   a	   tri-­‐functional	   protein,	   suggesting	   that	  
these	   activities	   act	   together,	   or	   in	   sequence	   –	   i.e.	   after	  
the	   action	   of	   the	   final	   PKS	  module	   of	  MmpA,	   and	   im-­‐
mediately	   before	   THP	   formation	   (see	   intermediate	   25,	  
Scheme	  1	  below)	  	  
The	  ∆mupC	  mutant	  was	   also	   analysed	   and	   showed	   the	  
presence	  of	  three	  major,	  and	  various	  minor,	  metabolites	  	  	  
(Fig.	   4B(a)).	   The	   three	  major	   products	   (80%	   total	   PAs,	  
each	   ca.	   8	  mg.L-­‐1,	   Table	   1)	  were	   identified	   as	   the	   novel	  
mupirocin	  C1	  15	  and	  rearrangement	  product14	  mupirocin	  
C2	   16	   (presumably	   formed	   from	   15),	   and	   PA-­‐B	   2.	   Both	  
mupirocin	  C1	  and	  C2	  have	  C6	  and	  C7	  at	  the	  ketone	  oxi-­‐
dation	   level.	   The	   minor	   products	   (0.7–1.3	   mg.L-­‐1)	   were	  
analogous	  to	  those	  seen	  in	  WT:	  mupirocin	  W1	  5,	  W2	  6,	  
W4	  9,	  W5	  10,	  desepoxy-­‐PA-­‐B	  11,	  and	  macrolactone	  12.	  	  
The	  double	  mutant	  mmpE∆OR/∆mupC	  produced	  main-­‐
ly	   the	   10,11-­‐alkene	   containing	   PAs	  9,	   10,	   11	   (Fig.	   4B(b))	  
and	  a	  new	  product	  identified	  as	  desepoxy-­‐mupirocin	  C1	  
17.	   	  MupC	  was	   identified	   as	   a	  putative	  dienoyl-­‐CoA	   re-­‐
ductase11	  suggesting	  that	  it	  acts	  here	  on	  the	  enol	  ketones	  
15	  and	  17.	  A	  similar	  enone	  reductase	  activity	  has	  recently	  
been	  reported for	  a	  reductase	  from	  a	  Clostridium	  sp.	  	  







PA-A 1 47          
PA-B 2 3.8           7.6         7.1    
PA-C 3b 0.2     2.6         
mupirocin W1 5 0.5         0.8         0.8         0.9           2.0  
mupirocin W2 6a 0.3         0.9         1.3         1.3           2.2  
mupirocin W3 7a                <0.5  
mupirocin W6 8a                <1.0  
mupirocin W4 9a 0.4     1.1         1.3        0.8        0.8        0.8        1.1   
mupirocin W5 10a 0.4     2.4         1.6        1.1        2.1        1.4        2.3   
10,11-deoxy-PA-B 11 a,b 0.3     2.3          0.7        1.8        1.1        1.7   
PA-B macrolactone 12 a 2.1           1.3         1.5    
mupirocin C1 15 a            8.4         8.1    
mupirocin C2 16 a            7.8      
mupirocin C3 17 a,b             0.5          0.4   
mupirocin F1 18             8.4    
mupirocin F2 19a             8.1    
desepoxy-mupirocin F1 20a,b               1.3   
7-keto-mupirocin W4 21 a                    1.2 
7-keto-mupirocin W5 22 a                  <1.0 
  
Figure	  5.	  Feeding	  of	  isolated	  mupirocin	  metabolites	  to	  mutant	  strains	  of	  P.	  fluorescens.	  	  
which	  shows	  high	  homology	  to	  dienoyl	  CoA	  reductases.20	  
When	   the	  ∆mupF	   strain	   was	   examined	   (Fig.	   4B(c)),	   the	  
metabolite	   profile	   was	   almost	   identical	   to	   that	   from	  
∆mupC	   with	   the	   addition	   of	   the	   previously	   reported16	  
mupirocin	   F1	   18a	   containing	   a	   6-­‐hydroxy,	   7-­‐keto	  moiety	  
(along	   with	   50%	   of	   its	   8-­‐epimer	   18b)	   and	   its	   epoxide-­‐
mediated	   rearrangement	   (see	   Scheme	   S1)	   product	  mupi-­‐
rocin	  F2	   19	   as	  additional	  major	   (ca	  8	  mgL-­‐1)	  metabolites.	  
The	  minor	  metabolite	  yields	  were	  essentially	   identical	   to	  
those	  in	  the	  ∆mupC	  mutant.	  
As	   with	   ∆mupC,	   formation	   of	   the	   double	   mutant	  
mmpE∆OR/∆mupF	  simplified	  the	  metabolite	  profile	  	  
	  (Fig.	  4B(d))	  which	  was	  very	  similar	  to	  mmpE∆OR/∆mupC	  
apart	   from	   a	   new	   metabolite	   which	   was	   identified	   as	  
desepoxy-­‐mupirocin	   F1	   20,	   	   the	   10,11-­‐alkene	   analogue	   of	  
mupirocin	  F1	  18.	  This,	  and	  the	  results	  from	  the	  single	  mu-­‐
tant	   ∆mupF,	   are	   consistent	   with	   MupF	   acting	   as	   a	   7-­‐
ketoreductase	  with	  both	  hydroxy-­‐ketones	  18	  and	  20.	  	  
Metabolites	  from	  double	  mutants	  ∆mupW/∆mupC	  and	  
∆mupW/∆mupU	   are	   identical	   to	   those	   of	   single	   mutant	  
∆mupW	   (Fig.	  S3)	  and	  no	  other	  metabolites	   from	  the	  sin-­‐
gle	  mutants,	  ∆mupC	  or	  ∆mupU,	  are	  present:	  this	  confirms	  
that	  	  MupW	  acts	  before	  MupO,	  MupU,	  MupV	  and	  MupC.	  
The	  ∆mupC/∆mupF	  double	  mutant	  is	  identical	  to	  the	  sin-­‐
gle	   mutant	   ∆mupC	   confirming	   that	   MupC	   acts	   before	  
MupF.	  Interestingly,	  re-­‐examination	  of	  the	  strain	  in	  which	  
the	  KR	  domain	   (KR6)	  responsible	   for	   initial	   reduction	  at	  
C7	  during	  PKS	  assembly	  has	  been	  deleted,	  led	  to	  isolation	  
of	   the	   previously	   reported19	   truncated	   product	   mupiric	  
acid	   13,	   along	   with	   the	   7-­‐keto	   analogues	   21	   and	   22	   of	  
mupirocin	  W4	  and	  W5.	  Thus	  a	  7-­‐hydroxyl	  group	  is	  clearly	  
required	  for	  action	  of	  MmpEOR	  and	  MupW/T.	  
No	  compounds	   lacking	  a	  6-­‐OH	  have	  been	  detected.	  The	  
gene	  responsible	  for	  6-­‐hydroxylation	  has	  not	  been	  defini-­‐
tively	   identified	   but	   must	   function	   before	   the	   HCS	   cas-­‐
sette	  as	  evidenced	  by	  the	  isolation	  of	  mupirocin	  H	  14	  from	  
mutation	  of	  any	  of	   the	  HCS	  cassette	  genes,19	  or	  either	  of	  
the	  MmpA	  twin	  acyl	  carrier	  proteins.12	  Mutation	  of	  mupA	  
which	   encodes	   a	   putative	   FMNH-­‐dependent	   oxygenase	  
again	   gives	   the	   shunt	  metabolite	  mupiric	   acid	   13	   as	   the	  
only	   detectable	   product.	   Thus	   6-­‐hydroxylation	   may	   be	  
controlled	  by	  mupA,	  and	  seems	  to	  be	  essential	  for	  further	  
processing	  along	  the	  main	  pathway.	  	  
	  
Chemical	  complementation	  experiments.	  	  
To	   further	   clarify	   the	   later	   stages	   of	   the	   biosynthetic	  
pathways	   and	   to	   identify	   the	   substrates	   for	   the	   later-­‐
acting	   enzymes,	   a	   series	   of	   feeds	   to	   small-­‐scale	   cultures	  
(25	  mL)	  were	  performed.	  Metabolites	  were	  fed	  to	  the	  mu-­‐
tant	  strains	  immediately	  after	  inoculation	  and	  the	  extracts	  
were	  analysed	  by	  HPLC-­‐MS	  (Fig.	  5	  and	  Fig.	  S4).	  We	  first	  
fed	   PA-­‐C	   3	   to	  ∆mupW	   in	   which	   the	  mmpE	   gene	   is	   still	  
intact	   and	   could	   potentially	   catalyse	   10,11-­‐epoxidation.	  
After	   60	   hours	   fermentation,	  mupirocin	  W1	   5	   and	  W2	  6	  
were	   produced	   as	   normal,	   but	   no	  metabolism	  of	   PA-­‐C	   3	  
and	   no	   production	   of	   PA-­‐A	   1	   was	   detected.	   This	   is	   con-­‐
sistent	   with	   PA-­‐A	   1	   and	   PA-­‐C	   3	   being	   formed	   from	   a	  
common	   intermediate	   by	   parallel	   pathways	   that	   diverge	  
at	   10,11-­‐epoxidation.	   To	   further	   confirm	   this	   PA-­‐B	   2	   was	  
fed	  to	  mutants	  ∆mupW	  and	  mmpE∆OR.	  PA-­‐A	  1	  was	  pro-­‐
duced	  in	  both	  cases	  with	  conversion	  rates	  of	  35	  and	  20%	  
respectively.	   (Fig.	   5	   and	   Fig.	   S4(a)	   and	   (d)),	   consistent	  
with	  PA-­‐B	  2	  being	  an	   intermediate	  on	  the	  main	  pathway	  
to	  PA-­‐A	  1,	   (Scheme	  1)	  as	  originally	  proposed	  by	  Mantle.18	  	  
On	   feeding	   the	   10,11-­‐alkene	   analogue	   11	   of	   PA-­‐B	   to	  
∆mupW,	  PA-­‐C	  3	   is	  produced	  (7%	  conversion,	  Figs.	  5	  and	  
S4(b)),	  but	  no	  PA-­‐A	  1.	  Thus,	  neither	  PA-­‐C	  3	  nor	  the	  10,11-­‐
alkene	  analogue	  of	  PA-­‐B	  11	  or	  intermediates	  derived	  from	  
it	   can	   be	   the	   actual	   substrate	   for	   MmpEOR.	   Thus,	   it	  
seems	  that	  MmpEOR	  acts	  before	  MupW/T	  and	  the	  paral-­‐
lel	  pathways	  must	  be	  active	  at	   the	   same	   time	   in	   the	  WT	  
strain	  since	  both	  epoxidised	  and	  non-­‐epoxidised	  interme-­‐
diates	  (see	  24	  and	  25,	  Scheme	  1)	  can	  be	  processed	  to	  gen-­‐
erate	  analogous	  products.	  
Mupirocin	  W4	  9	   and	  W5	   10	   were	   also	   fed	   to	   the	  mupH	  
strain,	   in	   which	   biosynthesis	   is	   truncated	   at	   the	   β-­‐
methylation	   (15-­‐methyl)	   stage.19	   No	   transformation	   of	  
mupirocin	  W4	  9	  was	  observed,	  but	  mupirocin	  W5	  10	   (C7	  
side	   chain)	   was	   elongated	   to	   mupirocin	   W4	   9	   (C9	   side	  
chain)	   indicating	   that	   these	   intermediates	   can	   be	   taken	  
up	   and	  metabolised	   by	   the	   cells	   (Fig	   S4i).	   This	   suggests	  
that	   once	   the	   fatty	   acid	   side-­‐chain	   elongation	   is	   under-­‐
way,	  THP	  ring	  formation	  is	  not	  possible,	  again	  consistent	  
with	  both	  MmpEOR	  and	  MupW/T	  acting	  after	  polyketide	  
assembly	  and	  before	  fatty	  acid	  side	  chain	  elaboration.	  
Additions	  of	  the	  enol-­‐ketone	  mupirocin	  C1	  15	   to	  deletion	  
strains	   of	  ∆mupU,	  ∆mupV,	  ∆mupO,	   and	  ∆macpE	   (which	  
all	  produce	  PA-­‐B	  2	  but	  no	  PA-­‐A	   1)	  all	   (e.g.	  Fig	  S4e)	  gave	  	  
good	   conversion	   to	   PA-­‐A	   1	   with	  most	   of	   the	   unincorpo-­‐
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Scheme	  1.	  Biosynthetic	  pathway	  to	  mupirocin	  and	  related	  metabolites.	  Structures	  of	  intermediates	  on	  the	  main	  pathway	  
are	  shown.	  For	  minor	  pathway	  and	  other	  compounds,	  see	  Figs	  3	  and	  4.	  
product	   mupirocin	   C2	   16.	   Similarly	   PA-­‐A	   was	   obtained	  
(Fig	   S4j)	   on	   feeding	   mupirocin	   F1	   18	   to	   ∆mupV.	   These	  
experiments	  confirm	  that	  MupC	  acts	  as	  an	  enone	  reduc-­‐
tase,11	  and	  MupF	  as	  a	  7-­‐ketoreductase.	  
	  
CONCLUSIONS	  
We	  have	  elucidated	  details	  of	  the	  pathway	  to	  PA-­‐B	  2	  and	  
established	   its	   intermediacy	   in	   PA-­‐A	   1	   biosynthesis.	   The	  
efficient	   transformation	   of	   PA-­‐B	   2	   to	   PA-­‐A	   1	   and	   the	  
switch	   to	  PA-­‐B	  2	   only	  production	  on	  mutation	  of	   any	  of	  
mupU,	  V,	  O,	  C,	  F	  and	  macpE	  suggests	  that	  modification	  of	  
the	   pyran	   ring	   occurs	   after	   elaboration	   of	   the	   9-­‐
hydroxynonanoic	  acid	  moiety	  on	  monic	  acid.	  This	  is	  con-­‐
sistent	  with	   the	  pathway	  shown	   in	  Scheme	   1	   in	  which	  β-­‐
keto	  ester	  23,	  produced	  by	  the	  modular	  PKS	  proteins	  en-­‐
coded	  by	  mmpD,	  mmpA	  and	  mmpC,	  along	  with	  the	  puta-­‐
tive	  oxidase	  mupA,	   is	   the	   substrate	   for	   the	  HCS	  cassette	  
to	  give	  the	  acyclic	  monic	  acid	  thioester	  24.	  Thioester	  24	   is	  
then	  epoxidised	  to	  give	  25	  and	  cyclised	  to	  26	  which	  is	  the	  
substrate	   for	   stepwise	   fatty	   acid	   elongation	   to	   PA-­‐B	   2.	  
This	  is	  then	  transferred	  (MupU)	  to	  MacpE	  where	  it	  is	  oxi-­‐
dised	  (MupO),	  dehydrated	  (MupV)	  and	  stepwise	  reduced	  
(MupC	  and	  MupF)	  to	  give	  PA-­‐A	  1.	  It	  appears	  that	  release	  
of	   PA-­‐B	   from	  MmpB	   is	   dependent	   on	   the	   action	   of	   the	  
terminal	   thioesterase	   (TE)	   domain.	   A	  mmpBΔTE	  mutant	  
gives	  only	  the	  mupiric	  acid/mupirocin	  H	  phenotype.	  This	  
is	   further	   supported	   by	   the	   isolation	   of	  macrolactone	   12	  
from	  WT	   and	  ΔmupC	   and	  ΔmupF	   strains.	   	   It	   is	   unlikely	  
that	   macrocyclisation	   could	   be	   spontaneous	   and	   it	   sug-­‐
gests	  that	  the	  TE	  domain	  can	  accept	  either	  the	  13-­‐OH	  or	  
water	  to	  give	  both	  intramolecular	  or	  intermolecular	  cata-­‐
lysed	  release.	  
Isolation	  of,	  e.g.	  mupirocins	  6,	  7,	  10	  and	  22,	  containing	  
shorter	   fatty	   acid	   side	   chains	   demonstrates	   that,	   while	  
monic	  acids	  lacking	  the	  THP	  ring	  can	  act	  as	  substrates	  for	  
MmpB-­‐dependent	   9HN	   elongation,	   it	   is	   inefficient,	   con-­‐
sistent	  with	  MupW/T	  acting	  	  before	  MmpB.	  
PA-­‐C	  3,	  previously	  assumed	  to	  be	  a	  precursor	  to	  PA-­‐A	  1	  
is	   formed	  by	  a	  minor	  parallel	  pathway.	  Several	  of	   the	   in-­‐
termediates	  involved	  in	  these	  parallel	  pathways	  were	  iso-­‐
lated	  from	  a	  series	  of	  single	  and	  double	  mutants	  and	  their	  
involvement	   demonstrated	   by	   their	   transformation	   to	  
either	  PA-­‐C	  3	  or	  PA-­‐A	   1	  on	  re-­‐feeding	   to	  mutant	  strains.	  
We	  have	   identified	   the	  gene	  responsible	   for	  epoxidation.	  
This	  occurs	  at	  the	  end	  of	  assembly	  of	  the	  monic	  acid	  moi-­‐
ety	  24	  as	  indicated	  by	  lack	  of	  epoxidation	  on	  mupiric	  acid	  
13	  and	  mupirocin	  H	  14	  but	  epoxidation	  has	  taken	  place	  in	  
formation	   of	   the	   acyclic	   monic	   acid,	   mupirocin	   W6	   8.	  
Thus	   epoxidation	   can	   occur	   before	   MupW	   and	   MupT	  
catalysed	   THP	   ring	   formation	   and	   ring	   formation	   is	   not	  
essential	   for	   epoxidation.	   Nevertheless,	   since	   in	   all	   mu-­‐
tant	   strains	   and	   WT,	   non-­‐epoxy	   metabolites	   appear	   in	  
very	   low	   titres,	   epoxidation,	   like	   THP	   ring	   formation	  
seems	  to	  be	   important	  for	   further	  processing	  of	   interme-­‐
diates	  by	  later	  stage	  enzymes.	  Thus	  our	  goal	  of	  engineer-­‐
ing	  P.	   fluorescens	  to	  give	  high	  titres	  of	  only	  PA-­‐C	  may	  be	  
unachievable	   and	  other	  means	  of	   achieving	   this	   are	   cur-­‐
rently	  being	  explored.	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